Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
SAN DIEGO --(BUSINESS WIRE)--Jan. 21, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.
View HTML
Toggle Summary Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held
View HTML
Toggle Summary Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
Spotlight Presentation at SABCS showed that in 38% of patients the HER2 status of the metastatic cancer differed from the primary tumor, offering new information to aid treatment decisions SAN DIEGO --(BUSINESS WIRE)--Dec. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular
View HTML
Toggle Summary Quest Diagnostics Now Offers Biocept’s Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics
Targeted Lung Panel Now Available with Physician’s Order at Quest’s 2,200 Patient Service Centers Nationwide SECAUCUS, N.J. AND SAN DIEGO – December 1, 2021 – Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics
View HTML
Toggle Summary Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
Biocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect
View HTML
Toggle Summary Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case
View HTML
Toggle Summary CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology.
View HTML
Toggle Summary Biocept Reports Third Quarter 2021 Financial Results
Revenues for the third quarter of $17.5 million , up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated
View HTML
Toggle Summary Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
Abstract published in the Journal of Molecular Diagnostics shows 200-1,000 times increase in assay sensitivity with the addition of Switch-Blocker technology SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
View HTML
Toggle Summary Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15,
View HTML